Migraine

RegulatoryAugust 6, 2026

FDA Submission Update for NURTEC ODT (Rimegepant Sulfate) by Pfizer

Pfizer has submitted a supplemental application for NURTEC ODT (Rimegepant Sulfate) under NDA212728 with a standard review priority.

ClinicalAugust 5, 2026

Rimegepant Study in Adolescents with Frequent Migraine Begins Enrollment

A clinical trial is underway to evaluate the safety and efficacy of rimegepant in adolescents suffering from frequent migraines.

ClinicalAugust 2, 2026

Eptinezumab shows promise for migraine prevention in new study

A multicentric study is underway to assess the effectiveness and tolerability of eptinezumab for migraine prevention.

RegulatoryJuly 24, 2026

FDA Acceptance of Ubrogepant Application by MSN Laboratories

The FDA has accepted the application for Ubrogepant submitted by MSN Laboratories.

ClinicalJuly 17, 2026

Eptinezumab Trial for Pediatric Migraine Participants Initiated by Lundbeck

A clinical trial is underway to evaluate the efficacy of eptinezumab in reducing episodic migraine days in pediatric patients.

StrategyJuly 16, 2026

FDA Submission for Ubrogepant by Zydus Pharmaceuticals

Zydus Pharmaceuticals has submitted an ANDA for Ubrogepant, indicating a potential generic entry into the migraine treatment market.

ClinicalJuly 14, 2026

Long-term Atogepant Study Shows Real-World Effectiveness for Migraine Prevention

A prospective multicentre observational study is evaluating atogepant's long-term effectiveness and safety for migraine prevention in real-world settings.

RegulatoryJuly 14, 2026

FDA Approves Supplemental Application for NURTEC ODT by Pfizer

The FDA has approved a supplemental application for NURTEC ODT, an oral medication containing rimegepant sulfate.

ClinicalJuly 7, 2026

APT Comparison Study to Evaluate Atogepant vs. Topiramate and Propranolol for Migraine Prevention

The APT Comparison Study will evaluate the effectiveness and tolerability of atogepant against topiramate and propranolol in migraine prevention.

ClinicalJuly 3, 2026

Study on Predicting Migraine Attack Pain Using Hemodynamic Monitoring

A study is underway to predict migraine attack pain using premonitory symptoms and real-time hemodynamic monitoring.

RegulatoryJune 30, 2026

FDA Approves Supplemental Application for AJOVY (Fremanezumab)

The FDA has approved a supplemental application for AJOVY, a migraine treatment by Teva Pharmaceuticals.

RegulatoryJune 30, 2026

FDA Accepts Supplement for VYEPTI (EPTINEZUMAB-JJMR) by Lundbeck

The FDA has accepted a supplemental application for VYEPTI, an anti-CGRP therapy for migraine.

ClinicalJune 24, 2026

AbbVie initiates trial for ubrogepant in menstrual migraine treatment

AbbVie is conducting a study to evaluate the safety and efficacy of ubrogepant for treating menstrual migraine in adult women.

RegulatoryJune 21, 2026

FDA Accepts Supplement for AJOVY (Fremanezumab) by Teva Pharmaceuticals

The FDA has accepted a supplemental application for AJOVY (fremanezumab) from Teva Pharmaceuticals.

RegulatoryJune 20, 2026

FDA Accepts Supplement for VYEPTI (EPTINEZUMAB-JJMR) by Lundbeck

The FDA has accepted a supplemental application for VYEPTI, an anti-CGRP therapy for migraine.

StrategyJune 18, 2026

Cipla's ANDA214209 for Sumatriptan Receives Abbreviated Approval from FDA

Cipla has received Abbreviated Approval (AP) from the FDA for its ANDA214209 application for Sumatriptan.

Companies

Assets

Recent signals(16)

FDA Submission Update for NURTEC ODT (Rimegepant Sulfate) by Pfizer

Rimegepant Study in Adolescents with Frequent Migraine Begins Enrollment

Eptinezumab shows promise for migraine prevention in new study

FDA Acceptance of Ubrogepant Application by MSN Laboratories

Eptinezumab Trial for Pediatric Migraine Participants Initiated by Lundbeck

FDA Submission for Ubrogepant by Zydus Pharmaceuticals

Long-term Atogepant Study Shows Real-World Effectiveness for Migraine Prevention

FDA Approves Supplemental Application for NURTEC ODT by Pfizer

APT Comparison Study to Evaluate Atogepant vs. Topiramate and Propranolol for Migraine Prevention

Study on Predicting Migraine Attack Pain Using Hemodynamic Monitoring

FDA Approves Supplemental Application for AJOVY (Fremanezumab)

FDA Accepts Supplement for VYEPTI (EPTINEZUMAB-JJMR) by Lundbeck

AbbVie initiates trial for ubrogepant in menstrual migraine treatment

FDA Accepts Supplement for AJOVY (Fremanezumab) by Teva Pharmaceuticals

FDA Accepts Supplement for VYEPTI (EPTINEZUMAB-JJMR) by Lundbeck

Cipla's ANDA214209 for Sumatriptan Receives Abbreviated Approval from FDA

Upcoming catalysts

Indications

Get signals before the market moves